Alumis Management
Management criteria checks 1/4
Alumis' CEO is Matt Babler, appointed in Sep 2021, has a tenure of 3.17 years. total yearly compensation is $4.59M, comprised of 11.2% salary and 88.8% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth $857.21K. The average tenure of the management team and the board of directors is 3.2 years and 2.5 years respectively.
Key information
Matt Babler
Chief executive officer
US$4.6m
Total compensation
| CEO salary percentage | 11.2% |
| CEO tenure | 3.2yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.2yrs |
| Board average tenure | 2.5yrs |
Recent management updates
No updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$239m |
| Jun 30 2024 | n/a | n/a | -US$189m |
| Mar 31 2024 | n/a | n/a | -US$169m |
| Dec 31 2023 | US$5m | US$516k | -US$155m |
Compensation vs Market: Matt's total compensation ($USD4.59M) is above average for companies of similar size in the US market ($USD2.24M).
Compensation vs Earnings: Insufficient data to compare Matt's compensation with company performance.
CEO
Matt Babler (59 yo)
3.2yrs
Tenure
US$4,591,749
Compensation
Mr. Martin Babler, also known as Matt, Ph D., serves as an Independent Director at 89bio, Inc. since April 13, 2024. He serves as the Chairperson at Sardona Therapeutics, Inc. He serves as President, Chief...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.2yrs | US$4.59m | 0.17% $ 857.2k | |
| Chief Scientific Officer | 3.2yrs | US$1.04m | 0.40% $ 2.0m | |
| Chief Business & Legal Officer | 3.2yrs | US$1.04m | 0.33% $ 1.7m | |
| Chief Financial Officer | 2.5yrs | no data | no data | |
| Senior VP and Head of People & Culture | 1.4yrs | no data | no data | |
| Head of Discovery & Esker Fellow | 3.2yrs | no data | no data | |
| Senior VP & Head of Immunology and Translational Science | 3.2yrs | no data | no data | |
| Senior VP of Pharmacology & Project Team Leader | 3.2yrs | no data | no data | |
| Chief Medical Officer | 2.3yrs | no data | no data | |
| Senior VP & Head of Clinical Development & Translational Medicine | 2.2yrs | no data | no data | |
| Chief Development Officer | 3.5yrs | no data | 0.077% $ 396.5k | |
| Senior VP & Head of Technical Operations | 2.8yrs | no data | no data |
3.2yrs
Average Tenure
59yo
Average Age
Experienced Management: ALMS's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.2yrs | US$4.59m | 0.17% $ 857.2k | |
| Independent Director | no data | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 2.3yrs | no data | 0% $ 0 | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 2.8yrs | no data | no data | |
| Independent Director | 3.3yrs | no data | 0.043% $ 222.1k |
2.5yrs
Average Tenure
59yo
Average Age
Experienced Board: ALMS's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.